Lung cancer UPDATE: July 20-28, 2016 :: Public Health Genomics Knowledge Base (v1.0)

Public Health Genomics Knowledge Base (v1.0)



July 20-28, 2016 




Last Updated: Jul 21, 2016

• A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
  Yoon Se-Lyun, et al. Experimental & molecular medicine 2016 0 (7) e246
• Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations.
  Zonta Eleonora, et al. PloS one 2016 0 (7) e0159094
• Truncating and Missense PPM1D Mutations in Early-Onset and/or Familial/Hereditary Prostate Cancer Patients.
  Cardoso Marta, et al. Genes, chromosomes & cancer 2016 7
• DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
  Rulli Eliana, et al. Tumori 2016 7 0
• Synergistic association of CYP1A1 polymorphisms with increased susceptibility to squamous cell lung cancer in north Indian smokers.
  Girdhar Yashila, et al. The International journal of biological markers 2016 7 0
• Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules.
  Dai Jie, et al. Lung cancer (Amsterdam, Netherlands) 2016 8 22-8
• Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population.
  Zanetti Krista A, et al. Lung cancer (Amsterdam, Netherlands) 2016 8 33-42
• Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
  Mok Tony, et al. Lung cancer (Amsterdam, Netherlands) 2016 8 1-8
• EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.
  Sheikine Yuri et al. Clinical lung cancer 2016 Jun
• Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
  Park Sojung, et al. BMC cancer 2016 0 417
• Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis.
  Liu Yinghui, et al. Thoracic cancer 2016 7 (4) 406-14
• Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.
  Pu Dan, et al. Thoracic cancer 2016 7 (4) 428-36
• Gefitinib for asymptomatic brain metastasis from advanced non-small cell lung cancer: Report of a favourable outcome.
  Liu Wen-Yang, et al. Thoracic cancer 2016 7 (4) 498-502
• Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC.
  Qin Yijia, et al. Thoracic cancer 2016 7 (4) 422-7
• Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).
  Fukuda Minoru, et al. Thoracic cancer 2016 7 (4) 467-72

• CDC Information (2)
• CDC-Authored Pub (7)

• Human (30)
• Pathogen (0)

• Human (3858)
• Pathogen (0)

• Human (60)
• Pathogen (0)

• Guidelines (8)
• Tier Table (4)
• Synthesis (10)

• Huamn (4)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB